低卵巢反应患者拮抗剂方案中戊酸雌二醇预处理不增加获卵数:一项随机对照试验
这项非盲随机对照试验于2017年11月至2021年3月纳入552例低卵巢反应不孕女性,比较黄体期口服戊酸雌二醇预处理与不预处理在拮抗剂方案中的效果。主要终点获卵数两组无显著差异,预处理组重组FSH使用时间和总剂量显著更高。
要点
- 戊酸雌二醇预处理组与对照组获卵数无显著差异(3.2 vs 3.4,治疗差-0.18,95%CI -0.67~0.32,P=0.49)。
- 预处理组重组FSH使用时间10.3天 vs 对照组8.6天,总剂量3081 IU vs 2548 IU,均显著更高。
- 临床妊娠率预处理组19.3%(23/119) vs 对照组28.7%(43/150),差异未达统计学显著(P=0.08)。
核心结论
- 在低卵巢反应患者中,拮抗剂方案联合黄体期口服戊酸雌二醇预处理未增加获卵数,临床妊娠率两组亦无显著差异。
研究设计与样本
- 非盲随机对照试验,2017年11月至2021年3月在一家生殖中心纳入552例按博洛尼亚标准定义的低卵巢反应不孕女性。
- 研究组于排卵后第7天至下次月经第2天口服戊酸雌二醇2 mg每日两次,两组均使用重组FSH促排卵,主导卵泡平均直径≥13 mm时启动GnRH拮抗剂0.25 mg/日。
- 主要终点为两组获卵总数,次要终点包括MII卵数、重组FSH使用时间与总剂量、优质胚胎率和临床妊娠率。
主要发现
- 获卵数(均值[SD])预处理组3.2[2.8] vs 对照组3.4[2.6],治疗差-0.18(95%CI -0.67~0.32,P=0.49)。
- MII卵数预处理组2.9[2.5] vs 对照组3.1[2.4],均值差-0.23(95%CI -0.69~0.23,P=0.16)。
- 优质胚胎数预处理组1.0[1.3] vs 对照组1.20[1.6],均值差-0.23(95%CI -0.50~0.04,P=0.19)。
- 重组FSH使用时间预处理组10.3[2.2]天 vs 对照组8.6[2.1]天,均值差1.7(95%CI 1.3~2.2,P=0.00);总剂量预处理组3081[680] IU vs 对照组2548[649] IU,均值差553.7(95%CI 405.8~661.6,P=0.00)。
- 临床妊娠率预处理组19.3%(23/119) vs 对照组28.7%(43/150),均值差-0.09(95%CI -0.20~0.01,P=0.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性为患者脱落率高,部分患者因预测成功率低和经济原因未返院治疗。
- 固定300 IU重组FSH剂量可能不足以显示两组间获卵数的差异。
- 作者指出需要更多研究探讨低卵巢反应患者是否需要预处理以及哪种预处理更合适。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does luteal phase estrogen valerate pretreatment improve oocyte yield and clinical outcomes in patients with low ovarian response during ovarian stimulation with the antagonist protocol? SUMMARY ANSWER: Pretreatment with oral estrogen valerate from Day 7 after ovulation to Day 2 of the next menstrual cycle did not increase oocyte yield in patients with a low ovarian response compared to no pretreatment. WHAT IS KNOWN ALREADY: Previous studies showed that patients with a normal ovarian response can obtain better clinical outcomes after pretreatment with estrogen in the antagonist protocol. For patients with advanced age and low ovarian response, it remains unclear if estrogen valerate pretreatment with the antagonist protocol yields more oocytes and improves pregnancy outcomes. STUDY DESIGN, SIZE, DURATION: This non-blinded randomized controlled trial (RCT) was conducted between November 2017 and March 2021. Participants were 552 women with low response who requested IVF treatment. The primary endpoint was comparison of the total number of retrieved oocytes between the two groups. The secondary endpoints were the total number of retrieved metaphase II (MII) oocytes, duration and total dosage of recombinant FSH (rFSH), good-quality embryo rate and clinical pregnancy rate. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study was conducted at a reproductive center. The RCT enrolled 552 infertile women with a low ovarian response (according to the Bologna criteria) who were undergoing IVF. In the study group, on Day 7 after ovulation patients were administered oral estrogen valerate (2 mg twice a day) until Day 2 of their next menstruation. Ovary stimulation was performed using rFSH, and a GnRH antagonist (0.25 mg/day) was started when a dominant follicle had a mean diameter ≥13 mm. MAIN RESULTS AND THE ROLE OF CHANCE: No significant difference was observed in the number (mean [SD]) of oocytes retrieved from the estrogen valerate pretreatment and control group (3.2 [2.8] versus 3.4 [2.6], respectively). The treatment difference was -0.18 (95% CI -0.67, 0.32, P = 0.49). No significant differences were observed in the number of MII oocytes (2.9 [2.5] versus 3.1 [2.4], mean difference -0.23, 95% CI (-0.69, 0.23), P = 0.16) and good-quality embryos (1.0 [1.3] versus 1.20 [1.6], mean difference -0.23, 95% CI (-0.50, 0.04), P = 0.19) between the two groups. The duration of rFSH treatment was significantly longer in the estrogen valerate pretreatment group than in the control group (10.3 [2.2] versus 8.6 [2.1] days, mean difference 1.7, 95% CI (1.3, 2.2), P = 0.00), and the total rFSH dosage was significantly higher in the estrogen valerate pretreatment group than in the control group (3081 [680] versus 2548 [649] IU, mean difference 553.7, 95% CI (405.8, 661.6), P = 0.00). The clinical pregnancy rate in the pretreatment group (19.3% [23/119]) was not significantly different from that in the control group (28.7% [43/150]). The mean difference was -0.09, 95% CI (-0.20, 0.01), P = 0.08. LIMITATIONS, REASONS FOR CAUTION: The major limitation was the high dropout rate of patients. Some patients did not return to the hospital for treatment because of predicted low success rates and for economic reasons. In addition, it is possible that the fixed dose of 300 IU rFSH was not sufficient to see differences in oocyte yield between the groups. WIDER IMPLICATIONS OF THE FINDINGS: Estrogen valerate pretreatment with an antagonist protocol did not increase oocyte yield in patients with low ovarian response. Similar to the number of retrieved oocytes, there was no significant difference in clinical pregnancy rate between estrogen pretreatment group and control group. More research is needed on whether patients with low ovarian response need pretreatment and which pretreatment is more appropriate. STUDY FUNDING/COMPETING INTEREST(S): This study was supported in part by a research grant from the Investigator-Initiated Studies Program of MSD (China) Holding Co., Ltd. and Organon (Shanghai) Pharmaceutical Technology Co., Ltd. (Grant number: IIS 56284). The authors declare that they have no competing interests regarding authorship or publication of this study. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT03300518. TRIAL REGISTRATION DATE: 28 September 2017. DATE OF FIRST PATIENT’S ENROLMENT: 15 November 2017.
引用
- Zhang S, Tang Y, Wang X, et al. Estrogen valerate pretreatment with the antagonist protocol does not increase oocyte retrieval in patients with low ovarian response: a randomized controlled trial. Hum Reprod. 2022. PMID: 35460400. doi:10.1093/humrep/deac081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。